Warning Labels as a Public Health Intervention: Effects and Challenges for Tobacco, Cannabis, and Opioid Medications
- PMID: 38166502
- PMCID: PMC12278888
- DOI: 10.1146/annurev-publhealth-060922-042254
Warning Labels as a Public Health Intervention: Effects and Challenges for Tobacco, Cannabis, and Opioid Medications
Abstract
Warning labels help consumers understand product risks, enabling informed decisions. Since the 1966 introduction of cigarette warning labels in the United States, research has determined the most effective message content (health effects information) and format (brand-free packaging with pictures). However, new challenges have emerged. This article reviews the current state of tobacco warning labels in the United States, where legal battles have stalled pictorial cigarette warnings and new products such as electronic cigarettes and synthetic nicotine products pose unknown health risks. This article describes the emerging research on cannabis warnings; as more places legalize recreational cannabis, they are adopting lessons from tobacco warnings. However, its uncertain legal status and widespread underestimation of harms impede strict warning standards. The article also reviews opioid medication warning labels, suggesting that lessons from tobacco could help in the development of effective and culturally appropriate FDA-compliant opioid warning labels that promote safe medication use and increased co-dispensing of naloxone.
Keywords: cannabis; opioid medications; tobacco; warning labels.
Conflict of interest statement
DISCLOSURE STATEMENT
The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.
Figures



References
-
- Al-Hamdani M, Joyce KM, Park T, Cowie ME, Stewart SH. 2021. Cannabis packaging: an opportunity for facilitating informed decisions. J. Consumer Aff. 55:1150–68
-
- Allard NC, Kruger JS, Kruger DJ. 2023. Cannabis advertising policies in the United States: state-level variation and comparison with Canada. Cannabis Cannabinoid Res. 8:505–9 - PubMed
-
- Bailey SC, Shrank WH, Parker RM, Davis TC, Wolf MS. 2009. Medication label improvement: an issue at the intersection of health literacy and patient safety. J. Commun. Healthc. 2:294–307
-
- Barry RA, Glantz SA. 2017. Lessons from tobacco for developing marijuana legalization policy. Rep., Cent. Tob. Control Res. Educ., Univ. Calif., San Francisco. http://www.escholarship.org/uc/item/87j477b7
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources